3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
5
Neoplasms
2
Thrombosis
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Pulmonary Embolism
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Cyclophosphamide
36
fludarabine phosphate
32
Tacrolimus
28
Busulfan
24
Peripheral Blood Stem Cell Transplantation
23
Mycophenolic Acid
20
Whole-Body Irradiation
19
Antilymphocyte Serum
18
Methotrexate
16
fludarabine
14
ruxolitinib
13
Melphalan
12
Cyclosporine
12
thymoglobulin
8
Stem Cell Transplantation
8
Radiotherapy
8
Methylprednisolone
8
Sirolimus
6
Prednisone
6
Cord Blood Stem Cell Transplantation
6
Specimen Handling
5
Filgrastim
5
Etoposide
5
Alemtuzumab
5
merphos
4
itacitinib
4
Imatinib Mesylate
4
INCB039110
4
Hematopoietic Stem Cell Transplantation
4
Cytarabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Primary Myelofibrosis
×
apixaban
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled